Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Jevtana is a prescription microtubule inhibitor containing cabazitaxel. It is used with prednisone for metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen. Treatment is administered by intravenous infusion.
read more about jevtana ...Cabazitaxel binds to tubulin, promotes tubulin assembly into microtubules, and inhibits microtubule disassembly. The resulting microtubule stabilization interferes with mitotic and interphase cellular functions.
Jevtana is used in patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen. It is given with daily prednisone. A neutrophil count at or below 1500 cells per cubic millimeter and severe liver impairment are contraindications.
The recommended dose is 20 mg per square meter by intravenous infusion over one hour every three weeks with prednisone 10 mg by mouth daily throughout treatment. A dose of 25 mg per square meter can be used in selected patients. Premedication is given before each infusion to reduce hypersensitivity risk.
Jevtana carries boxed warnings for neutropenia and severe hypersensitivity. Neutropenic deaths have occurred, and blood counts are monitored frequently. Other serious concerns include bone marrow suppression, severe gastrointestinal reactions, kidney failure, respiratory disorders, liver impairment, and fetal harm.
Jevtana treats metastatic castration-resistant prostate cancer after prior treatment with a docetaxel-containing regimen.
The recommended dose is 20 mg per square meter by intravenous infusion every three weeks with daily prednisone.
The labeled infusion time is one hour.
Yes. The boxed warnings concern neutropenia and severe hypersensitivity.
Cabazitaxel. https://www.cancer.gov/about-cancer/treatment/drugs/cabazitaxel. Date Accessed October 6, 2026.
Cabazitaxel Injection: MedlinePlus Drug Information. https://www.medlineplus.gov/druginfo/meds/a611009.html. Date Accessed October 6, 2026.
Drugs Approved for Prostate Cancer. https://www.cancer.gov/about-cancer/treatment/drugs/prostate. Date Accessed October 6, 2026.
JEVTANA (Cabazitaxel) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa. Date Accessed October 6, 2026.
Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel Treatment: A Randomised Open-Label Trial. https://pubmed.ncbi.nlm.nih.gov/20888992/. Date Accessed October 6, 2026.